To the Editor, We approached with considerable intrigue the prospective cohort study conducted by Wang et al, which scrutinizes serum lipid metabolites as prognostic indicators for joint arthroplasty in individuals afflicted with hip/knee osteoarthritis (OA)1. The authors’ pioneering utilization of Fine P1.347 mmol/L) represents a significant advancement in the realm of personalized management. Nonetheless, these thresholds necessitate validation across a spectrum of cohorts and OA phenotypes. A pronounced correlation between hip OA and lipid levels was observed in comparison with knee OA (P <0.001), likely indicative of underlying biomechanical and vascular disparities. The integration of site-specific thresholds with obesity metrics (e.g., HDL-C ≤1.3 mmol/L for obese women with hip OA) could enhance risk stratification. Furthermore, external validation within multi-ethnic populations is imperative, given that the homogeneity of the UK Biobank (95.8% White) imposes limitations on generalizability. Lastly, while lipoprotein(a) and triglycerides exhibited no significant associations, triglycerides may exert an indirect influence on OA through crystalline arthropathies. Broadening biomarker panels to encompass oxidized LDL or lipoprotein-associated phospholipase A2 (Lp-PLA2) may elucidate residual pathways. In conclusion, the pioneering work of Wang et al positions lipid metabolites as prognostic instruments for OA; however, the mechanistic and phenotypic subtleties warrant further exploration. The application of functional lipidomics, triad-targeted interventions, and the establishment of validated site-specific thresholds have the potential to transition lipid biomarkers from mere predictors to modifiable therapeutic targets, ultimately delaying the necessity for arthroplasty among high-risk OA populations.
Lu et al. (Wed,) studied this question.